GRAND PHARMA (00512) Introduces World's First Epinephrine Nasal Spray for Severe Allergic Reactions

Stock News2025-12-23

GRAND PHARMA (00512) announced a product collaboration agreement with Youer Pharmaceutical Technology (Shanghai) Co., Ltd. (Youer Pharma). The group secured exclusive commercialization rights for Neffy® (Youminsu®), the world's first epinephrine nasal spray for emergency treatment of Type I allergic reactions (including severe anaphylaxis) in adults and pediatric patients (2mg for ≥30kg; 1mg for 15-30kg), in mainland China and non-exclusive rights in Hong Kong SAR.

The partnership, led by GRAND PHARMA (Beijing) Co., Ltd., plans to achieve localized production within 24 months of regulatory approval. Youer Pharma specializes in pediatric-focused innovative medicines, aiming to introduce safe and convenient treatments for Chinese children through global partnerships and local R&D.

Neffy®, the first FDA-approved non-injectable anaphylaxis treatment in 35 years, is expected to improve access to epinephrine therapy for severe allergy patients in China and address the gap in out-of-hospital emergency care. Post-launch, GRAND PHARMA will leverage its established emergency care resources and distribution network to accelerate market penetration.

With its portability and user-friendly design, Youminsu® could rapidly expand into household, school, and travel settings, becoming a new growth driver for GRAND PHARMA's cardiovascular emergency segment. This segment covers acute rescue and chronic disease management, with over 30 products—14 listed in China's emergency medicine catalog and 16 in the shortage drug list.

The pipeline includes 20+ cardiovascular R&D projects, combining proprietary innovation with complex generic breakthroughs. GRAND PHARMA remains committed to addressing unmet clinical needs through global partnerships and dual-cycle development strategies, enhancing its portfolio to deliver advanced therapies worldwide.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment